Vaxart (VXRT) News Today $0.37 -0.03 (-8.48%) Closing price 04:00 PM EasternExtended Trading$0.38 +0.01 (+1.74%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period B. Riley Comments on Vaxart's Q1 Earnings (NASDAQ:VXRT)March 31 at 1:17 AM | americanbankingnews.comB. Riley Issues Positive Outlook for Vaxart EarningsVaxart, Inc. (NASDAQ:VXRT - Free Report) - B. Riley lifted their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarteMarch 31 at 1:16 AM | marketbeat.comVaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. RileyB. Riley cut their target price on Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a report on Thursday.March 28, 2025 | marketbeat.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPSVaxart (NASDAQ:VXRT - Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.March 21, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Issues Earnings ResultsVaxart (NASDAQ:VXRT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.March 21, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comVaxart Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Short Interest UpdateVaxart, Inc. (NASDAQ:VXRT - Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, an increase of 17.0% from the February 13th total of 11,350,000 shares. Based on an average daily volume of 1,960,000 shares, the short-interest ratio is presently 6.8 days. Currently, 6.0% of the shares of the stock are sold short.March 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - Here's WhyMarch 14, 2025 | marketbeat.comVaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20March 14, 2025 | markets.businessinsider.comVaxart announces trial initiation of norovirus oral pill vaccine candidateMarch 11, 2025 | markets.businessinsider.comVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateMarch 11, 2025 | globenewswire.comVaxart (VXRT) to Release Earnings on ThursdayVaxart (NASDAQ:VXRT) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comVaxart (VXRT) Projected to Post Quarterly Earnings on ThursdayVaxart (NASDAQ:VXRT) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comVaxart announces norovirus vaccine candidate trial data publishedMarch 5, 2025 | markets.businessinsider.comVaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly AdultsMarch 5, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average - Should You Sell?March 4, 2025 | marketbeat.comMultimillion-dollar Biden-era COVID-19 vax project halted by Trump’s HHSFebruary 26, 2025 | msn.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?February 13, 2025 | marketbeat.comVaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of DirectorsJanuary 28, 2025 | markets.businessinsider.comVaxart appoints Kevin Finney to board of directorsJanuary 28, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Should You Sell?January 17, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Here's WhyJanuary 16, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Here's What HappenedJanuary 16, 2025 | marketbeat.comVaxart highlights progress of COVID-19, norovirus, influenza programsJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review To Continue COVID-19 Phase 2b Trial; Stock UpJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical TrialJanuary 13, 2025 | globenewswire.comVaxart project agreement change ups funding for oral COVID vaccine candidateDecember 28, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average - Here's WhyDecember 21, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Time to Sell?December 13, 2024 | marketbeat.comVaxart completes enrollment in Phase 2b study evaluating its COVID-19 pillDecember 3, 2024 | markets.businessinsider.comVaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateDecember 2, 2024 | globenewswire.comSio Capital Management LLC Decreases Holdings in Vaxart, Inc. (NASDAQ:VXRT)Sio Capital Management LLC lowered its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,608,244 shares of the biotechnology compNovember 29, 2024 | marketbeat.comB. Riley Forecasts Vaxart's FY2024 Earnings (NASDAQ:VXRT)Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley raised their FY2024 earnings per share estimates for shares of Vaxart in a research note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnNovember 21, 2024 | marketbeat.comFY2027 Earnings Estimate for Vaxart Issued By B. RileyVaxart, Inc. (NASDAQ:VXRT - Free Report) - Stock analysts at B. Riley issued their FY2027 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will earn $0.09 perNovember 20, 2024 | marketbeat.comVaxart reports inducement grants under Nasdaq listing ruleNovember 20, 2024 | markets.businessinsider.comVaxart’s Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy RatingNovember 19, 2024 | markets.businessinsider.comVaxart (VXRT) Receives a Buy from OppenheimerNovember 14, 2024 | markets.businessinsider.comVaxart’s Q3 2024: Progress in Oral Vaccine DevelopmentNovember 14, 2024 | markets.businessinsider.comVaxart, Inc. (VXRT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comVaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comVaxart (VXRT) to Release Earnings on WednesdayVaxart (NASDAQ:VXRT) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 8, 2024 | marketbeat.comVaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13November 7, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comVaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024October 24, 2024 | markets.businessinsider.comVaxart will present research on COVID-19, norovirus vaccine candidatesOctober 24, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Time to Sell?October 24, 2024 | marketbeat.com Remove Ads Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Media Mentions By Week VXRT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VXRT News Sentiment▼0.390.78▲Average Medical News Sentiment VXRT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VXRT Articles This Week▼91▲VXRT Articles Average Week Remove Ads Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNDL News Today Rapport Therapeutics News Today Stoke Therapeutics News Today REGENXBIO News Today Mereo BioPharma Group News Today Eton Pharmaceuticals News Today Cartesian Therapeutics News Today Entrada Therapeutics News Today Heron Therapeutics News Today Ginkgo Bioworks News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VXRT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VXRT Stock Free VXRT Stock Alerts